Comment on: “Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis”
Restricted accessLetterFirst published online 2026
Comment on: “Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis”
WarliSMSihombingBKadarDD, et al. Comparison of long-term survival for muscle-invasive bladder cancer patients who underwent bladder preservation therapy and radical cystectomy: A systematic review and meta-analysis. Urol J2025; 92: 585–594. https://doi.org/10.1177/03915603251347444
2.
FahmyOKhairul-AsriMGSchubertT, et al. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol2018; 36(2): 43–53. https://linkinghub.elsevier.com/retrieve/pii/S107814391730529X
3.
BrückKMeijerRPBoormansJL, et al. Disease-free survival of patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder-preserving therapy: a nationwide study. Int J Radiat Oncol2024; 118(1): 41–49. https://linkinghub.elsevier.com/retrieve/pii/S0360301623076861
4.
ZlottaARBallasLKNiemierkoA, et al. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol2023; 24(6): 669–681. https://linkinghub.elsevier.com/retrieve/pii/S1470204523001705
5.
TotaroAPintoFBresciaA, et al. Imaging in bladder cancer: Present role and future perspectives. Urol Int2010; 85(4): 373–380. https://doi.org/10.1159/000321279
6.
BizzarriFPNelsonAWColquhounAJ, et al. Utility of fluorodeoxyglucose positron emission tomography/computed tomography in detecting lymph node involvement in comparison to conventional imaging in patients with bladder cancer with variant histology. Eur Urol Oncol2025; 8: 1459–1460. https://linkinghub.elsevier.com/retrieve/pii/S2588931125000975
7.
BenderRFriedeTKochA, et al. Methods for evidence synthesis in the case of very few studies. Res Synth Methods2018; 9(3): 382–392. https://doi.org/10.1002/jrsm.1297
8.
DahlDMKarrisonTGMichaelsonMD, et al. Long-term outcomes of chemoradiation for muscle-invasive bladder cancer in noncystectomy candidates. Final results of NRG Oncology RTOG 0524-A phase 1/2 trial of paclitaxel + trastuzumab with daily radiation or paclitaxel alone with daily irradiation. Eur Urol Oncol2024; 7(1): 83–90. https://linkinghub.elsevier.com/retrieve/pii/S2588931123001153
9.
GuptaSFujiiYVan Der HeijdenMS, et al. Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC). J Clin Oncol2024; 42(4_suppl): ts720. https://doi.org/10.1200/jco.2024.42.4_suppl.tps720
10.
SuerEHamidiNGokceMI, et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy. World J Urol2016; 34(6): 847–851. https://doi.org/10.1007/s00345-015-1710-5
11.
Grobet-JeandinEPinarUParraJ, et al. Health-related quality of life after curative treatment for muscle-invasive bladder cancer. Nat Rev Urol2023; 20(5): 279–293. https://www.nature.com/articles/s41585-022-00693-z
12.
BrückKAtemaVLeliveldAM, et al. Health-related quality of life in patients treated for nonmetastatic muscle-invasive bladder cancer: radical cystectomy versus bladder-preserving therapy. Int J Radiat Oncol2025; 123(4): 1004–1017. https://linkinghub.elsevier.com/retrieve/pii/S0360301625045092
13.
GandiCVaccarellaLBientinesiR, et al. Bladder cancer in the time of machine learning: Intelligent tools for diagnosis and management. Urol J2021; 88(2): 94–102. https://doi.org/10.1177/0391560320987169
14.
PloussardGDaneshmandSEfstathiouJA, et al. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol2014; 66(1): 120–137. https://linkinghub.elsevier.com/retrieve/pii/S0302283814001675
15.
SherryADStewartALuoG, et al. Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization. J Radiat Oncol2019; 8(4): 395–403. https://doi.org/10.1007/s13566-019-00411-0
16.
WitjesJABabjukMBellmuntJ, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multistakeholder effort. Eur Urol2020; 77(2): 223–250. https://linkinghub.elsevier.com/retrieve/pii/S0302283819307638
17.
BizzarriFPCampetellaMRussoP, et al. Risk factors for benign uretero-enteric anastomotic strictures after open radical cystectomy and ileal conduit. Urol J2025; 92(2): 224–230. https://doi.org/10.1177/03915603241303634
